Lightnews — Scholar-powered news

Tom Marjot @tom-marjot.bsky.social · Aug 11

Really nice to be hosting the BASL #MASLD SIG at Jesus College Oxford on 5th September

📢Attendance is FREE and registration is EASY. There are still a few spaces left.
🔗(tinyurl.com/4j8esadr)

Really great mix of speakers. AM = Basic/Translational science; PM = Clinical updates

Programme for BASL MASLD SIG meeting 5th September 2025

Venue details for BASL MASLD SIG meeting 5th September 2025

2

Tom Marjot @tom-marjot.bsky.social · May 25

🔗 shorturl.at/aFO1Q

Mechanism underpinning muscle pathology in MASLD and impact of exercise on liver histology

Tom Marjot @tom-marjot.bsky.social · May 25

📢Great to write this review for Hep Comms with Matt Armstrong & @jonathanstinemd.bsky.social

💪We've covered everything you need to know about #Muscle & #MASLD
- Insulin resistance
- Sarcopenia
- Myosteatosis
- Impact of weight loss drugs
- Benefits of exercise

🔗 shorturl.at/aFO1Q

#LiverSky

Graphic showing assessment methods for various domains of muscle quality and function in patients with MASLD including insulin resistance, myosteatosis, sarcopenia, and frailty.

1 2 11

Reposted by Tom Marjot

Jonathan G. Stine, MD MSc, FACP @jonathanstinemd.bsky.social · May 23

It was an absolute delight to contribute to this high-impact work with @tom-marjot.bsky.social and @mattarmstrong95.bsky.social in which we review all things #MASLD and #Muscle!

If you're looking for holiday weekend reading, look no further:

journals.lww.com/hepcomm/page...

@ebtapper.bsky.social

Skeletal muscle and MASLD: Mechanistic and clinical insights : Hepatology Communications

, which all converge on the liver to drive disease progression and adverse patient outcomes. This review explores the mechanistic links between skeletal muscle and MASLD, including the role of abnorma...

journals.lww.com

2 8

Reposted by Tom Marjot

Rui Castro @ruicastrohd.bsky.social · Apr 15

BS @easlnews.bsky.social Congress

Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social

& more!🔗https://tinyurl.com/4ky9r3x9

1 4 9

Reposted by Tom Marjot

Eric Topol @erictopol.bsky.social · Mar 6

In these unprecedented dark times for American life science and medical research (no less well beyond biomedicine), my coping mechanism is to laser focus on the unremitting and remarkable daily advances, and the fervent hope these will not be slowed or interrupted.

28 150 1.3K

Tom Marjot @tom-marjot.bsky.social · Mar 17

#LiverSky

Tom Marjot @tom-marjot.bsky.social · Mar 17

Breakthroughs Beyond the Journal @jhepatology.bsky.social

🚨The liver is central to fructose-associated cancer

▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes

Can this explain link between MASLD & extra-hepatic cancer?

Highlights from latest article in Breakthroughs Beyond the Journal in Journal of Hepatology. It showcases work published in Nature.

2

Tom Marjot @tom-marjot.bsky.social · Mar 17

Original paper in @nature.com :
🔗https://shorturl.at/jcWYE
👏 @gjpattij.bsky.social

BBJ article in Journal of Hepatology:
🔗https://shorturl.at/4E2qT
@jhepatology.bsky.social
@easlnews.bsky.social

3

Tom Marjot @tom-marjot.bsky.social · Mar 17

Breakthroughs Beyond the Journal @jhepatology.bsky.social

🚨The liver is central to fructose-associated cancer

▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes

Can this explain link between MASLD & extra-hepatic cancer?

1 1 6

Reposted by Tom Marjot

Elliot Tapper @ebtapper.bsky.social · Jan 25

There has been a recent influx to #gisky and #liversky

To sustain this, you need to be active. If you were a lurker, no we need your pearls, papers, and pets. Post. Use the hashtags. Build.

2 15 47

Reposted by Tom Marjot

Rui Castro @ruicastrohd.bsky.social · Jan 24

Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit

Huge attendance and interest! 👏🏼

@tom-marjot.bsky.social @madsisraelsen.bsky.social

2 4

Reposted by Tom Marjot

EASL @easlnews.bsky.social · Jan 15

2025 is the perfect year to take your career to the next level🚀

There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.

Apply by 20 January: easl.eu/leadership25

#LiverSky

5 12

Reposted by Tom Marjot

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Jan 6

By @adhanda.bsky.social & @tom-marjot.bsky.social

#Sharedit link: rdcu.be/d5rwu

5 9

Reposted by Tom Marjot

Lorenz Adlung Lab @adlunglab.com · Jan 5

Thoughtful piece from Marjot & Dhanda (@adhanda.bsky.social) in @natrevgastrohep.bsky.social: Alcohol-free drinks show promise for motivated individuals to reduce alcohol consumption but may pose relapse risks in others. Balance is key for clinical guidance. 🧪
www.nature.com/articles/s41...

Alcohol-free and low-strength drinks: friend or foe? - Nature Reviews Gastroenterology & Hepatology

Consumption of no and low-alcohol (NoLo) beverages is now commonplace in modern society. However, the debate surrounding the relative risks and benefits of these products is nuanced and evolving, part...

www.nature.com

2 3 6

Reposted by Tom Marjot

Ashwin Dhanda @adhanda.bsky.social · Jan 3

Do read my comment piece with @tom-marjot.bsky.social on NoLo alcohol 👇🏾

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Jan 3

JAN ISSUE | COMMENT

Alcohol-free and low-strength drinks: friend or foe?

www.nature.com/articles/s41...

#Liversky #Gastrosky

A quote from an article about alcohol-free drinks stating: "alcohol drinkers are twice as likely to consume alcohol-free drinks than non-drinkers"

1 4 6

Tom Marjot @tom-marjot.bsky.social · Jan 2

🔗Original paper from Xie et al.👏: shorturl.at/T6xkg

🔗Breakthroughs Beyond the Journal: shorturl.at/8lae8

Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin

Xie et al. show that myocardial infarction (MI) accelerates the hepatic pathological progression of MASLD by promoting the production of CCR2+Ly6Chi monocytes, triggering hepatic immunoinflammatory response, and upregulating cardiac periostin contents, which in turn acts on hepatocytes and stellate cells to promote hepatic lipid accumulation and fibrosis.

shorturl.at

2

Tom Marjot @tom-marjot.bsky.social · Jan 2

1: In 2025, look out for a new section in Journal of Hepatology: "Breakthroughs Beyond the Journal". Editorial-style analyses of pivotal liver research. #LiverSky

2: My comment on work from Cell Metabolism showing that MI drives #MASH. The interaction between these two conditions works BOTH ways👇

New evidence of cross-disease communication between heart and liver

1 1 12

Tom Marjot @tom-marjot.bsky.social · Dec 17

Good to see you here @easlnews.bsky.social !

1 4

Reposted by Tom Marjot

NEJM.org @nejm.org · Dec 6

Hello, #MedSky community! We’re excited to begin our Bluesky journey.

Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

32 190 870

Reposted by Tom Marjot

Jonathan G. Stine, MD MSc, FACP @jonathanstinemd.bsky.social · Nov 27

#LiverSky Come join in T-minus 26 mins for EASL Studio! #Sarcopenia #Exercise #Nutrition #Frailty #MASLD #LiverTransplant

Jonathan G. Stine, MD MSc, FACP @jonathanstinemd.bsky.social · Nov 12

💪 Excited to join as a panelist alongside #ShelleyKeating #FelicityWilliams #JenniferLai for Episode 8 of @EASLnews #EASLStudio2024 discussing #Sarcopenia in chronic liver disease on Wed Nov 27!
Don’t miss it! #LiverHealth #Hepatology #ClinicalPractice

easl.eu/easl-studio-...

Sarcopenia: Converting research findings into clinical practice - Are we doing enough?

Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights ...

easl.eu

1 2

Reposted by Tom Marjot

Andrew Moon @andrewmmoon.bsky.social · Nov 27

Tumor seeding is a dreaded complication of biopsy for HCC. But how common is it?

A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years

#LiverSky

Link: journals.lww.com/ajg/abstract...

9 19

Tom Marjot @tom-marjot.bsky.social · Nov 26

#LiverSky

Useful tip...

There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:

1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'

This will collate📌posts in a tab on your home screen + ⬆️ engagement.

9 8 20

Tom Marjot @tom-marjot.bsky.social · Nov 26

📌

1